Publications

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group None., (2024), Diabetic medicine : a journal of the British Diabetic Association

Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.

Zayed MG. et al, (2024), JAMA Ophthalmol

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland

PREISS D. et al, (2023), BMJ Quality and Safety

Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.

Seekircher L. et al, (2023), Eur Heart J Open, 3

Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2022 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2022.

(2022), Circulation, 146, e569 - e605

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801

Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017.

Thalmann I. et al, (2022), Heart

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.

Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329

Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease

Kohli-Lynch CN. et al, (2022), Circulation

Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland

Thalmann I. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2328 - 2328

Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial

Preiss D. et al, (2022), CIRCULATION, 146, E577 - E577

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized trials

Preiss D. et al, (2022), DIABETES RESEARCH AND CLINICAL PRACTICE, 186

Impact of ACLY on type 2 diabetes in UK Biobank: a Mendelian randomisation study

Stiby A. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3011 - 3011

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials

PREISS D. et al, (2021), Diabetes Care

Cookies on this website

Publications